Physician profile
Robin E Traufler
NPI 1669474490
$11,502.24
in general payments reported to CMS, 2019-2025
27 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,204 · 2022: $4,662 · 2023: $1,836 · 2024: $2,072 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,635.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daxor Corporation | $2,849.99 | 2022 | |
| Abbott Laboratories | $1,979.22 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Alnylam Pharmaceuticals INC. | $995.09 | 2022-2025 | Onpattro |
| Boston Scientific Corporation | $751.25 | 2021-2025 | Watchman Access System, Resonate El Icd Vr |
| Novartis Pharmaceuticals Corporation | $739.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $515.59 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $509.97 | 2021-2025 | Uptravi, Opsumit |
| Pfizer INC. | $497.16 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.07 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $431.15 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $364.19 | 2021-2025 | Lifevest |
| Cvrx, INC. | $331.05 | 2021-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $235.20 | 2021-2025 | |
| Scpharmaceuticals INC. | $143.27 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $138.44 | 2022-2024 | Optimizer, Optimizer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $85.80 | 2025 | Attruby |
| Novo Nordisk INC | $83.76 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $82.18 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $79.50 | 2023-2025 | Eliquis, Camzyos |
| Vifor Pharma, INC. | $39.30 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $35.39 | 2023 | Inpefa |
| Recor Medical INC | $24.81 | 2024 | Paradise Renal Denervation System |
| Edwards Lifesciences Corporation | $23.04 | 2022 | |
| Atricure, INC. | $22.49 | 2024 | |
| Nuwellis, INC. | $20.70 | 2025 | Aquadex Smartflow Console |
| Daiichi Sankyo INC. | $17.27 | 2021 | |
| Medtronic, INC. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Traufler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.